CT83-directed bispecific antibody

A **CT83-directed bispecific antibody** is an investigational cancer immunotherapy concept rather than a clearly identified single named drug. In available public disclosures, the term refers to a **bispecific T-cell engager** designed to recognize the cancer-testis antigen **CT83**, also known as **KK-LC-1**, on tumor cells and recruit/activate T cells, typically through **CD3**, to kill CT83-expressing cancers. Publicly described programs include preclinical **KK-LC-1 or CT83/HLA-targeted T-cell engager antibodies** in solid tumors, particularly tumors such as gastric, lung, breast, and cervical cancers in which KK-LC-1 expression has been reported. Because the queried name does not uniquely identify a single proprietary molecule, developer, or exact binding format, it is best treated as a nonspecific reference to a preclinical **CT83-targeting bispecific antibody program** rather than a distinct drug product.

Other names

CT83-directed bispecific antibodyCT-83-directed bispecific antibodyCT 83-directed bispecific antibodyKK-LC-1-directed bispecific antibodyKK-LC1-directed bispecific antibodyKK-LC 1-directed bispecific antibody